LYZL1

Across TCGA pan-cancer cohorts, LYZL1 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of LYZL1’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where LYZL1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LYZL1 is over-expressed in tumor, although a few such as PRAD and KICH show the opposite, repressed pattern.

KIRC, KIRP, and PRAD are the cancer types where LYZL1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LYZL1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	II,III,IV	+0.363	<.001	8	view →
KIRP	All	All	+0.123	<.001	7	view →
PRAD	All	All	−0.083	.009	2	view →
BRCA	All	All	+0.056	.010	2	view →
KICH	All	All	−0.020	.010	2	view →
CHOL	All	All	−0.194	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

LYZL1–KIRC

Open the KIRC breakdown →